Public ivermectin trial results show no clear hospitalization benefit after control and endpoint checks

What can large public randomized-trial results establish about ivermectin for acute outpatient COVID-19? A targeted aggregate-data audit covers 5 comparisons from 4 platforms, with 9152 reported analysis-population records. The directly reported hospital-or-death outcomes at the common follow-up window include 6984 records and yield an exploratory pooled risk ratio of 1.167 (95% modified Hartung-Knapp confidence interval 0.418 to 3.261). Replacing concurrent PRINCIPLE controls with all historical controls changes that trial's crude risk ratio from 1.054 to . Adding every hospital/death union compatible with TOGETHER's published margins yields conditional pooled intervals, all containing no difference. These computations do not establish a hospitalization benefit, but uncertainty, outcome differences, and aggregate-only access prevent concluding that every possible effect is absent.